

SecureEMR version 5.0 Real World Testing Plan

Developer Name:	Inmediata Health Group
Product Name:	SecureEMR
Version Number:	5.0
CHPL ID:	15.07.07.2769.SE01.01.00.1.210408
RWT Page URL:	https://www.mysecureemr.com/SecureEMRv5-ONC-RWT-Plan.pdf



Testing Plan

Justification for Real World Testing Approach

Inmediata Health Group will be conducting a Real World Testing using SecureEMR 5.0 to measure the end-user engagement and effectiveness of the E-Prescribing [criteria 170.315(b)(3)] module of our EHR.

E-Prescribing is a very important module to our end-users and their patients since it simplifies the process for fulfilling and renewing prescriptions.

Our approach is to use deidentified analytics reports to measure the use of electronic prescriptions transactions (new prescriptions and refill requests) from our providers.

We will also measure the error rate for the transactions submitted to our e-prescriptions clearinghouse to demonstrate our compliance with NCPDP Standard V2017071.

Standards Updates (SVAP and USCDI)

NCPDP Standard V2017071

Care Setting

Ambulatory

Overall Expected Outcome

- Real World Testing will show a high rate of usage in the prescription module with our providers in comparison to those users that are not using this module
- Real World Testing will show a higher rate of electronic prescriptions in comparison to those prescriptions sent by fax to the pharmacies
- Real World Testing will show a low rate of errors from our prescription hub

Measures Used

Measure #1

- **Certification Criteria:**

170.315(b)(3) E-Prescribing

- **Justification**

E-Prescribing is a very important module to our end-users and their patients since it simplifies the process for fulfilling and renewing prescriptions. We will be using an analytics method since it would use real world usage from customers to measure the success of this module of the system.

- **Test Methodology**

Our approach is to use deidentified analytics reports to measure the use of electronic prescriptions transactions (new prescriptions and refill requests) from our providers.

We will also measure the error rate for the transactions submitted to our e-prescriptions clearinghouse to demonstrate our compliance with NCPDP Standard V2017071.

- **Expected Outcome**

1. Real World Testing will show a high rate of usage in the prescription module with our providers in comparison to those users that are not using this module
2. Real World Testing will show a higher rate of electronic prescriptions in comparison to those prescriptions sent by fax to the pharmacies
3. Real World Testing will show a low rate of errors from our prescription hub

Schedule of Key Milestones

Key Milestone	Date
Develop reports	1/21/2022
Execute preliminary reports	4/15/2022
Analyze preliminary reports	6/17/2022
Execute and analyze final reports	1/1/2023
Create final RWT Document	1/6/2023
Submit final RWT Document to ICSA Labs	2/2/2023

This Real World Testing plan is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Name: Camilo Torres

Authorized Representative Email: ctorres@inmediata.com

Authorized Representative Phone: 787-783-3233

Authorized Representative Signature: *Camilo Torres*

Date: 11/30/2021